Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead.

Abstract

At its height, the Clostridium difficile infection epidemic caused approximately 7000 infections and 300 deaths per day in the USA. Fecal microbiota transplantation (FMT) has demonstrated extraordinary clinical resolution, C. difficile infection cure rates of over 90%, and low recurrence. In tandem with the rise of FMT, the gastrointestinal microbiome has emerged as a 'vital' organ armed with a wealth of microbe 'soldiers' more powerful than known antibiotics. FMTs' reputation has diffused into many new 'indications' yet these appear to be merely the tip of the iceberg when considering its potential applications. FMT as a therapeutic tool has evolved from the original format of blended donor stool and moved towards a refined product comprising a myriad of microbial components, presented aesthetically as encapsulated lyophilized powder.

• Authors: Thomas Borody, Monika Fischer, Scott Mitchell, Jordana Campbell
• Journal: Expert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 9 Issue 11 Pg. 1379-91 ( 2015) ISSN: 1747-4132 [Electronic] England
• PMID: 26414076 (Publication Type: Journal Article, Review)

Topics

• Animals
• Diffusion of Innovation
• Fecal Microbiota Transplantation (adverse effects, trends)
• Feces (microbiology)
• Forecasting
• Gastrointestinal Diseases (diagnosis, microbiology, therapy)
• Gastrointestinal Microbiome
• Humans
• Intestines (microbiology)
• Treatment Outcome